Clinical Trial Update: A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating irinotecan, cisplatin, and celecoxib in patients with metastatic or unresectable esophageal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Camptosar (irinotecan)
• Platinol (cisplatin)

Snippet

Sponsor: University of Southern California | Conditions: Esophageal Cancer | Phase 2 | Status: TERMINATED